China to Delist TCM Drugs with 'Unknown' Labeling in Package Inserts

On May 9, 2026, China’s National Medical Security Administration (NMSA) released a draft proposal for the adjustment of the national essential drug list, proposing to delist traditional Chinese medicine (TCM) products whose package inserts list contraindications, adverse reactions, or precautions as ‘unknown’—and which fail to rectify such labeling within a stipulated timeframe. This move directly impacts TCM manufacturers, exporters, and regulatory compliance service providers, particularly those targeting international markets where product labeling integrity is a mandatory prerequisite for market access.

Event Overview

On May 9, 2026, the National Medical Security Administration (NMSA) published the Draft Proposal on the Adjustment of the National Basic Medical Insurance Drug List (2026 Edition). The draft explicitly identifies TCM products with package insert sections for ‘Contraindications’, ‘Adverse Reactions’, or ‘Precautions’ marked as ‘unknown’—and not updated to provide evidence-based information by the deadline—as priority candidates for removal from the national medical insurance reimbursement list.

Industries Affected by Segment

TCM Exporters and International Trade Enterprises

These enterprises are directly affected because many overseas regulators—including the U.S. FDA, the European Medicines Agency (EMA), and Australia’s Therapeutic Goods Administration (TGA)—require complete, clinically substantiated prescribing information as a condition for import clearance and marketing authorization. A domestic delisting signal reflects underlying data gaps that may already hinder registration dossiers in key export markets.

TCM Manufacturers and Formulation Developers

Manufacturers face increased pressure to generate or compile clinical safety data to revise labeling. Products previously marketed without robust post-marketing surveillance or pharmacovigilance infrastructure may now require urgent investment in real-world evidence collection, literature review, or targeted observational studies to meet both NMSA and foreign regulatory expectations.

Regulatory Affairs and Compliance Service Providers

Service providers supporting TCM exporters must now align domestic labeling updates with international dossier requirements. Inconsistencies—for example, an updated Chinese insert lacking corresponding translations or clinical rationale acceptable to EMA—may delay submissions or trigger additional queries during foreign review cycles.

Distributors and Import Agents in Emerging Markets

In Southeast Asia, the Middle East, and Latin America, local import agents often rely on Chinese regulatory status as informal credibility indicators. A domestic delisting—even at the draft stage—may trigger customs scrutiny or local health authority requests for supplementary documentation, increasing lead times and operational uncertainty.

Key Focus Areas and Practical Responses for Stakeholders

Monitor official timelines and clarification documents from NMSA

The draft remains open for public comment; final implementation dates, grace periods, and criteria for ‘sufficient’ labeling revisions have not yet been finalized. Stakeholders should track NMSA’s official notices and any accompanying technical guidance on acceptable evidence types (e.g., systematic literature reviews vs. new clinical trials).

Prioritize high-export-volume products with ‘unknown’ labeling

Focus initial revision efforts on SKUs with documented sales in FDA-, EMA-, or TGA-regulated markets—or those cleared for registration in ASEAN, GCC, or ANVISA jurisdictions. These products carry the highest risk of parallel regulatory impact if domestic labeling remains incomplete.

Distinguish between policy signaling and operational enforcement

The current draft signals tightening standards but does not yet constitute binding regulation. Companies should avoid premature supply chain adjustments (e.g., halting production or canceling orders) until the final version is published and implementation schedules confirmed.

Initiate cross-functional alignment on labeling updates

Coordinate internal teams—including R&D, pharmacovigilance, regulatory affairs, and international marketing—to jointly assess feasibility of updating each ‘unknown’ section. Where clinical data is genuinely unavailable, document justification pathways aligned with ICH guidelines (e.g., referencing WHO monographs or authoritative compendia) to support transitional labeling strategies.

Editorial Perspective / Industry Observation

Observably, this draft represents a regulatory signal—not an immediate outcome—aimed at incentivizing long-standing improvements in TCM product characterization. Analysis shows it reflects growing convergence between China’s domestic reimbursement policies and international expectations for pharmacovigilance transparency. From an industry perspective, it is better understood as a catalyst for proactive compliance planning rather than a sudden barrier. Continued attention is warranted because subsequent NMSA communications may clarify evidentiary thresholds, define ‘reasonable timeframes’, or link labeling completeness to other regulatory processes (e.g., GMP inspections or export certificate issuance).

This development underscores how domestic policy shifts can rapidly propagate into global market access conditions—especially for products whose regulatory foundations were historically built on traditional use rather than modern clinical evidence. It highlights the increasing importance of integrated regulatory strategy across domestic and international portfolios.

Conclusion

This NMSA draft does not introduce new scientific standards but reinforces existing expectations for evidence-informed labeling as a prerequisite for both reimbursement eligibility and international credibility. Its primary significance lies in accelerating the timeline for compliance action among TCM stakeholders. Currently, it is more appropriately interpreted as a structured warning—prompting systematic review of labeling gaps—rather than an imminent disqualification mechanism. Rational response requires measured prioritization, evidence-mapping, and coordinated cross-border regulatory planning—not reactive overcorrection.

Source Attribution

Main source: Draft Proposal on the Adjustment of the National Basic Medical Insurance Drug List (2026 Edition), issued by China’s National Medical Security Administration (NMSA), published May 9, 2026.
Points requiring ongoing observation: Final publication date of the revised drug list; definition of ‘stipulated timeframe’ for labeling updates; and whether NMSA will issue technical guidance on acceptable data sources for revising ‘unknown’ sections.